Publications by authors named "Stephane Nave"

Claim this Profile
H
Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent β-thalassaemia.
Ali T Taher, Vip Viprakasit, Maria Domenica Cappellini, Dominik Kraus, Patrick Cech, Stephane Nave

Br J Haematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Basmisanil, a highly selective GABA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man.
Joerg F Hipp, Frederic Knoflach, Robert Comley, Theresa M Ballard, Michael Honer, Stephane Nave

Sci Rep· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy.
Robert C Sergott, Giulia M Amorelli, Giovanni Baranello, Emmanuel Barreau, Shannon Beres, Stephane Nave

Ann Clin Transl Neurol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy.
Zhihua Li, Gary R Mirams, Takashi Yoshinaga, Bradley J Ridder, Xiaomei Han, Stephane Nave

Clin Pharmacol Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).
Stephane Nave, Rachelle S Doody, Mercè Boada, Timo Grimmer, Juha-Matti Savola

J Alzheimers Dis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
Edilio Borroni, Bernd Bohrmann, Fiona Grueninger, Eric Prinssen, Stephane Nave

J Pharmacol Exp Ther· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
Stefan Sturm, Anton Forsberg, Stephane Nave, Per Stenkrona, Nicholas Seneca

Eur J Nucl Med Mol Imaging· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty.
Philippe H Robert, Alexandra König, Hélene Amieva, Sandrine Andrieu, François Bremond, Stéphane Nave

Front Aging Neurosci· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contingent negative variation as a dopaminergic biomarker: evidence from dose-related effects of methylphenidate.
Anke M W Linssen, Eric F P M Vuurman, Anke Sambeth, Stephane Nave, Will Spooren

Psychopharmacology (Berl)· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889.
S Eralp Bellibas, Indra Patel, Emmanuel Chamorey, Bettyna Brivet, Ernest D Bush, Stephane Nave

Clin Cancer Res· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis